Advice on the use of superDimension Navigation System to help diagnostic sampling of peripheral lung lesions to aid local decision making
Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making
NICE has developed a medtech innovation briefing (MIB) on DyeVert for reducing contrast media in coronary and peripheral angiography
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
NICE has today, 30 January 2020, published a simple guide to the way we develop our guidance and standards.
More evidence on the clinical and cost effectiveness of esketamine needed
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance
Applications close on Wednesday 4 March 2020
NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
Dame Philippa Russell, Vice-President of Carers UK and Topic Adviser for the NICE guideline on Supporting Adult Carers
1 Abortion from 14 weeks up to 24 weeks: choosing between medical or surgical abortion Decision aid c NICE 2019. All rights reserved. Subject to...
1 Abortion before 14 weeks: choosing between medical or surgical abortion Decision aid c NICE 2019. All rights reserved. Subject to Notice of rights.
Submit a shared learning example
Listed below are the highly specialised technology evaluation block scoping reports which have been submitted to the Department of Health and Social...
How to submit a new medical technology to NICE for guidance
This guidance evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that: deliver treatment - like those...
Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.
This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.
Everything you need to know about the Cancer Drugs Fund (CDF) and the drugs we appraise.
On this page: What changes are we making? Get involved Who else is involved? Timeline Why we're making these changes Improvements
Explore data about our technology appraisal guidance
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
NICE board strategy meeting papers
To help people access the information they need quickly and easily, we're reviewing how we produce and present guidance.
Outside interests of the NICE board
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence
An outline of the key principles that are universal to all of NICE's guidance and standards.
Our procedures and policies - includes complaints, declarations of interest and data protection policies.
NICE transparency of spend
We produce guidance and quality standards to help reduce health inequalities, to improve access to healthcare and to encourage health improvement. We
Biographies of the NICE senior management team and minutes of their meetings
Our board sets out our strategic priorities and policies. The day to day decision-making is the responsibility of our senior management team . The...
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
This agreement relates to: Tezacaftor and ivacaftor (Symkevi®) in combination with ivacaftor (kalydeco) for treating cystic fibrosis patients who are
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
Technology appraisal and Highly specialised technologies appeals
Our position on use of the EQ-5D-5L valuation set for England
How we select the subjects for development into information, advice and guidance
Medtech guidance where there's no new research available that would effect the current guidance
The following NICE published diagnostics assessments have been transferred to the static list. Guidance is moved to the static list following...
Who can become a registered stakeholder? Registration is open to anyone with an interest in the topic who is one of the following: The company that
NICE guidelines are evidence-based recommendations for health and care in England.
We're aiming to increase and extend the use of data in the development and evaluation of our guidance. Data sources could include: electronic health
Our guidelines are based on the best available evidence. Our recommendations are put together by experts, people using services, carers and the public
NICE research projects and partners.
Patient access schemes and the NICE Patient Access Liaison Unit When assessing new drugs and treatments, NICE looks at the cost of the treatment and...